These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 9188573

  • 1. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
    Amtoft HW, Sørensen AB, Bareil C, Schmidt J, Luz A, Pedersen FS.
    J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
    [Abstract] [Full Text] [Related]

  • 2. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
    Ethelberg S, Hallberg B, Lovmand J, Schmidt J, Luz A, Grundström T, Pedersen FS.
    J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
    [Abstract] [Full Text] [Related]

  • 3. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
    Ethelberg S, Lovmand J, Schmidt J, Luz A, Pedersen FS.
    J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
    [Abstract] [Full Text] [Related]

  • 4. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.
    Nielsen AA, Sørensen AB, Schmidt J, Pedersen FS.
    J Virol; 2005 Jan; 79(1):67-78. PubMed ID: 15596802
    [Abstract] [Full Text] [Related]

  • 5. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
    Martiney MJ, Rulli K, Beaty R, Levy LS, Lenz J.
    J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
    [Abstract] [Full Text] [Related]

  • 6. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
    Sørensen KD, Quintanilla-Martinez L, Kunder S, Schmidt J, Pedersen FS.
    J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
    Ethelberg S, Tzschaschel BD, Luz A, Diaz-Cano SJ, Pedersen FS, Schmidt J.
    J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
    [Abstract] [Full Text] [Related]

  • 10. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
    Zaiman AL, Lewis AF, Crute BE, Speck NA, Lenz J.
    J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.
    Nieves A, Levy LS, Lenz J.
    J Virol; 1997 Feb; 71(2):1213-9. PubMed ID: 8995644
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.
    Zaiman AL, Lenz J.
    J Virol; 1996 Aug; 70(8):5618-29. PubMed ID: 8764076
    [Abstract] [Full Text] [Related]

  • 14. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.
    Morrison HL, Soni B, Lenz J.
    J Virol; 1995 Jan; 69(1):446-55. PubMed ID: 7983741
    [Abstract] [Full Text] [Related]

  • 15. An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo.
    Ethelberg S, Sørensen AB, Schmidt J, Luz A, Pedersen FS.
    J Virol; 1997 Dec; 71(12):9796-9. PubMed ID: 9371648
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Enhancer mutations of Akv murine leukemia virus inhibit the induction of mature B-cell lymphomas and shift disease specificity towards the more differentiated plasma cell stage.
    Sørensen KD, Kunder S, Quintanilla-Martinez L, Sørensen J, Schmidt J, Pedersen FS.
    Virology; 2007 May 25; 362(1):179-91. PubMed ID: 17258785
    [Abstract] [Full Text] [Related]

  • 18. A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus.
    Glud SZ, Sørensen AB, Andrulis M, Wang B, Kondo E, Jessen R, Krenacs L, Stelkovics E, Wabl M, Serfling E, Palmetshofer A, Pedersen FS.
    Blood; 2005 Nov 15; 106(10):3546-52. PubMed ID: 16051745
    [Abstract] [Full Text] [Related]

  • 19. Triple basepair changes within and adjacent to the conserved YY1 motif upstream of the U3 enhancer repeats of SL3-3 murine leukemia virus cause a small but significant shortening of latency of T-lymphoma induction.
    Ma SL, Lovmand J, Sørensen AB, Luz A, Schmidt J, Pedersen FS.
    Virology; 2003 Sep 01; 313(2):638-44. PubMed ID: 12954229
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.